Development of acute lympboblastic leukemia in a patient with increased hematogones after toxic bone marrow damage.
To the best of our knowledge we describe the first case showing the association of increased B cell precursors/hematogones in a regenerating post-toxic bone marrow with subsequent development of a B-ALL. Since all immunohistochemical/moleculargenetic anaylses have failed to identify the initial malignant leukemic clone, we suggest a close-meshed follow-up of such cases to identify potential mechanisms for the malignant transformation of B-cell precursors/hematogones and to prevent further fatal courses.
Gattenlöhner
Stefan
S
Institute of Pathology, University of Würzburg, Würzburg, Germany. stefan.gattenloehner@mail.uni-wuerzburg.de
Einsele
Hermann
H
D000328:Adult; D001402:B-Lymphocytes / Q000473:pathology*; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000150:complications* / Q000473:pathology; D002243:Carbolines / Q000009:adverse effects; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects; D010879:Piperazines / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000209:etiology* / Q000473:pathology; D011687:Purines / Q000009:adverse effects; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000009:adverse effects; D000068581:Tadalafil
D002243:Carbolines; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068581:Tadalafil; D000068677:Sildenafil Citrate
B-ALL; Bone marrow; hematogones; toxic damage